0001193125-21-296215 Sample Contracts

MiNK Therapeutics, Inc. (a Delaware corporation) Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
AutoNDA by SimpleDocs
INDEMNIFICATION AGREEMENT
Indemnification Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [_________], 2021, between MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), and [______] (“Indemnitee”).

MINK THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENT
Incentive Stock Option Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances)

This agreement (this “Agreement”) evidences a stock option granted by MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), to the individual named above (the “Participant”), pursuant to and subject to the terms of the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.

MINK THERAPEUTICS, INC. NON-STATUTORY STOCK OPTION AGREEMENT
Non-Statutory Stock Option Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances)

This agreement (this “Agreement”) evidences a stock option granted by MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), to the individual named above (the “Participant”), pursuant to and subject to the terms of the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.

AMENDMENT TO CONVERTIBLE PROMISSORY NOTE
Convertible Promissory Note • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

THIS AMENDMENT TO CONVERTIBLE PROMISSORY NOTE (this “Amendment”), dated as of September 29, 2021 (the “Effective Date”), is made between MiNK Therapeutics, Inc., a Delaware corporation (f/k/a AgenTus Therapeutics, Inc.; the “Company”) and Agenus Inc., a Delaware corporation (the “Holder”; together with the Company, the “Parties”).

MINK THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT
Restricted Stock Unit Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances)

This agreement (this “Agreement”) evidences a grant (the “Award”) of Restricted Stock Units (“RSUs”) by MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), to the individual named above (the “Participant”), pursuant to and subject to the terms of the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!